Porträt Prof. Dr. Kopka, Klaus; FWP

Prof. Dr. Klaus Kopka

Director Institute of Radio­pharma­ceutical Cancer Research
Phone: +49 351 260 2060

Marita Kersten

Secretariat / Administration
Institute of Radio­pharma­ceutical Cancer Research
Phone: +49 351 260 3223



Departments of Radiopharmaceutical Cancer Research

Medicinal RadiochemistryDepartment of Medicinal Radiochemistry

  • Small molecule and peptide-based radiotracer
  • Preclinical Characterization of Radioconjugates
  • Therapeutic Alpha-Emitters
  • Multi-targeted Radiotheranostics
  • Biological evaluation and modulation of targeted, radiometal-based bioconjugates

Radiopharmaceutical and Chemical BiologyDepartment of Radiopharmaceutical and Chemical Biology

  • Radiotracer and Drug Development
  • Theranostic Targets and Experimental Models
  • Radiopharmacology and Cancer Imaging
  • Tissue Remodeling and Inflammation Imaging
  • Radiometals and Functional Labeling Chemistry
  • Metabolic and Immune Imaging Biomarkers

Positron Emission TomographyDepartment of Positron Emission Tomography

  • Improved quantification of functional information in oncological PET
  • Quantitative perfusion imaging using functional ASL-MRI
  • Multimodal imaging and assessment of in vivo quantification accuracy
  • Motion compensation methods for PET
  • High resolution PET image reconstruction

RadioimmunologyDepartment of Radioimmunology

  • Antibody-based immunotheranostics for tumor therapy and diagnosis
  • Adapter CAR-based immunotheranostics for personalized immunotherapy and diagnosis
  • Modulation of tumor microenvironment
  • Development of immuno- and radiotherapy
  • Personalized immunotheranostics for acute myeloid leukemia

Nano-Microsystems for Life SciencesDepartment of Nano-Microsystems for Life Sciences

  • Bionanoelectronics
  • 3D Bioreactors
  • Droplets microfluidics for clinical diagnostics

NeuroradiopharmaceuticalsDepartment of Neuroradiopharmaceuticals

  • Molecular imaging of adenosine signalling in cancer
  • Molecular imaging of α7 nAChR in cancer and brain diseases
  • [18F]Flubatine - a potential PET marker of early Alzheimer`s disease
  • Development of new ligands and 18F-radiotracers for the vesicular acetylcholine transporter (VAChT) in brain
  • New PET Radioligands for Imaging of Cannabinoid Receptors Type 2 (CB2) in the Human Brain
  • Radioligands for PET Imaging of Cyclic Nucleotide Phosphodiesterases 2A, 5A and 10A
  • Development of 18F-labelled PET radiotracers for the imaging of σ receptors in cancer and brain diseases

Targetry, Target Chemistry and RadiopharmacyDepartment of Targetry, Target Chemistry and Radiopharmacy

  • Production of radioisotopes at the proton accelerator cyclotron TR-Flex by means of (p,X) nuclear reactions.
  • Development of new target technology, target preparation processes and processes for the separation and preparation of radionuclides.
  • Supply of the Institute for Radiopharmaceutical Cancer Research and external cooperation partners with radionuclides for research and development such as 18F, 11C, 64Cu, 67Cu, 131Ba, 133La, 197(m)Hg, ...
  • Providing PET radiopharmaceuticals for daily clinical use (18F-FDG, 18F-FDOPA, 18F-PSMA-1007, 18F-FMISO, 11C-methionine) according to GMP and AMG including quality control.
  • GMP-compliant transfer of newly developed radiotracers and manufacturing processes into clinical application.
  • Scaling of the processes for the generation of radionuclides and the production of radiopharmaceuticals to industrial scale and knowledge transfer to industrial partners.
  • Cooperation with external accelerator facilities to integrate alternative nuclear reactions into the nuclide production process.